Dual IGF1R/IR inhibitors in combination with GD2-CAR T-cells display a potent anti-tumor activity in diffuse midline glioma H3K27M-mutant.
CAR T-cells
DIPG
DMG
IGF1R/IR
immunotherapy
Journal
Neuro-oncology
ISSN: 1523-5866
Titre abrégé: Neuro Oncol
Pays: England
ID NLM: 100887420
Informations de publication
Date de publication:
01 07 2022
01 07 2022
Historique:
pubmed:
30
12
2021
medline:
8
7
2022
entrez:
29
12
2021
Statut:
ppublish
Résumé
Diffuse midline gliomas (DMG) H3K27M-mutant, including diffuse intrinsic pontine glioma (DIPG), are pediatric brain tumors associated with grim prognosis. Although GD2-CAR T-cells demonstrated significant anti-tumor activity against DMG H3K27M-mutant in vivo, a multimodal approach may be needed to more effectively treat patients. We investigated GD2 expression in DMG/DIPG and other pediatric high-grade gliomas (pHGG) and sought to identify chemical compounds that would enhance GD2-CAR T-cell anti-tumor efficacy. Immunohistochemistry in tumor tissue samples and immunofluorescence in primary patient-derived cell lines were performed to study GD2 expression. We developed a high-throughput cell-based assay to screen 42 kinase inhibitors in combination with GD2-CAR T-cells. Cell viability, western blots, flow-cytometry, real time PCR experiments, DIPG 3D culture models, and orthotopic xenograft model were applied to investigate the effect of selected compounds on DIPG cell death and CAR T-cell function. GD2 was heterogeneously, but widely, expressed in the tissue tested, while its expression was homogeneous and restricted to DMG/DIPG H3K27M-mutant cell lines. We identified dual IGF1R/IR antagonists, BMS-754807 and linsitinib, able to inhibit tumor cell viability at concentrations that do not affect CAR T-cells. Linsitinib, but not BMS-754807, decreases activation/exhaustion of GD2-CAR T-cells and increases their central memory profile. The enhanced anti-tumor activity of linsitinib/GD2-CAR T-cell combination was confirmed in DIPG models in vitro, ex vivo, and in vivo. Our study supports the development of IGF1R/IR inhibitors to be used in combination with GD2-CAR T-cells for treating patients affected by DMG/DIPG and, potentially, by pHGG.
Sections du résumé
BACKGROUND
Diffuse midline gliomas (DMG) H3K27M-mutant, including diffuse intrinsic pontine glioma (DIPG), are pediatric brain tumors associated with grim prognosis. Although GD2-CAR T-cells demonstrated significant anti-tumor activity against DMG H3K27M-mutant in vivo, a multimodal approach may be needed to more effectively treat patients. We investigated GD2 expression in DMG/DIPG and other pediatric high-grade gliomas (pHGG) and sought to identify chemical compounds that would enhance GD2-CAR T-cell anti-tumor efficacy.
METHODS
Immunohistochemistry in tumor tissue samples and immunofluorescence in primary patient-derived cell lines were performed to study GD2 expression. We developed a high-throughput cell-based assay to screen 42 kinase inhibitors in combination with GD2-CAR T-cells. Cell viability, western blots, flow-cytometry, real time PCR experiments, DIPG 3D culture models, and orthotopic xenograft model were applied to investigate the effect of selected compounds on DIPG cell death and CAR T-cell function.
RESULTS
GD2 was heterogeneously, but widely, expressed in the tissue tested, while its expression was homogeneous and restricted to DMG/DIPG H3K27M-mutant cell lines. We identified dual IGF1R/IR antagonists, BMS-754807 and linsitinib, able to inhibit tumor cell viability at concentrations that do not affect CAR T-cells. Linsitinib, but not BMS-754807, decreases activation/exhaustion of GD2-CAR T-cells and increases their central memory profile. The enhanced anti-tumor activity of linsitinib/GD2-CAR T-cell combination was confirmed in DIPG models in vitro, ex vivo, and in vivo.
CONCLUSION
Our study supports the development of IGF1R/IR inhibitors to be used in combination with GD2-CAR T-cells for treating patients affected by DMG/DIPG and, potentially, by pHGG.
Identifiants
pubmed: 34964902
pii: 6489024
doi: 10.1093/neuonc/noab300
pmc: PMC9248389
doi:
Substances chimiques
IGF1R protein, human
0
Receptor, IGF Type 1
EC 2.7.10.1
Receptor, Insulin
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1150-1163Subventions
Organisme : Cancer Research UK
ID : 11736
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 13982
Pays : United Kingdom
Commentaires et corrections
Type : CommentIn
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Neuro-Oncology.
Références
J Neuroimmunol. 2005 Dec 30;170(1-2):115-21
pubmed: 16313974
Neuro Oncol. 2021 Jan 30;23(1):34-43
pubmed: 33130881
Front Immunol. 2020 Apr 24;11:737
pubmed: 32391020
Br J Cancer. 2020 Mar;122(5):624-629
pubmed: 31857716
Nat Genet. 2012 Jan 29;44(3):251-3
pubmed: 22286216
Immunol Cell Biol. 2019 Aug;97(7):664-674
pubmed: 31009109
Annu Rev Med. 2017 Jan 14;68:139-152
pubmed: 27860544
Neuro Oncol. 2021 Aug 2;23(8):1231-1251
pubmed: 34185076
J Immunother Cancer. 2019 Jul 17;7(1):188
pubmed: 31315671
Cell Rep. 2017 Apr 11;19(2):225-234
pubmed: 28402847
Sci Transl Med. 2019 Nov 20;11(519):
pubmed: 31748226
Front Immunol. 2018 Jul 27;9:1740
pubmed: 30140266
Cancers (Basel). 2020 Mar 13;12(3):
pubmed: 32183246
Eur J Cancer. 2017 Mar;73:38-47
pubmed: 28161497
Front Biosci (Landmark Ed). 2009 Jan 01;14(1):352-75
pubmed: 19273072
Exp Cell Res. 2017 Nov 15;360(2):397-403
pubmed: 28947132
Cancer Cell. 2018 May 14;33(5):829-842.e5
pubmed: 29763623
Cancer Cell. 2017 Oct 9;32(4):520-537.e5
pubmed: 28966033
Cancer Lett. 2020 Aug 10;485:14-26
pubmed: 32417396
Int J Mol Sci. 2020 Sep 15;21(18):
pubmed: 32942636
J Clin Oncol. 2011 Oct 20;29(30):3999-4006
pubmed: 21931021
Oncoimmunology. 2018 Mar 15;7(6):e1433518
pubmed: 29872565
PLoS One. 2015 Mar 06;10(3):e0118926
pubmed: 25748921
Front Endocrinol (Lausanne). 2018 Jun 05;9:297
pubmed: 29922232
Blood. 2006 Dec 1;108(12):3890-7
pubmed: 16926291
J Neurooncol. 2019 Oct;145(1):177-184
pubmed: 31522324
Front Immunol. 2019 Feb 08;10:168
pubmed: 30800125
Mol Cancer Ther. 2011 Aug;10(8):1407-18
pubmed: 21659463
Cancer Discov. 2017 Dec;7(12):1404-1419
pubmed: 29025771
Childs Nerv Syst. 2020 Jan;36(1):39-46
pubmed: 31489454
Nature. 2012 Jan 29;482(7384):226-31
pubmed: 22286061
J Immunol. 2017 Sep 1;199(5):1616-1625
pubmed: 28724578
Clin Cancer Res. 2019 Apr 15;25(8):2560-2574
pubmed: 30655315
Nat Med. 2018 May;24(5):572-579
pubmed: 29662203
Acta Neuropathol Commun. 2018 Jun 28;6(1):51
pubmed: 29954445
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
J Immunol. 1986 Jun 1;136(11):3994-9
pubmed: 3517163
J Immunother. 1998 Jan;21(1):75-83
pubmed: 9456440
Nat Med. 2018 Aug;24(8):1204-1215
pubmed: 29967352
Pharmacol Res. 2018 Mar;129:194-203
pubmed: 29203440